PBF-1129 in Patients With NSCLC

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

May 1, 2024

Study Completion Date

August 1, 2024

Conditions

Locally Advanced or Metastatic NSCLC

Interventions

DRUG

PBF-1129

PBF-1129 once a day by oral administration

Trial Locations (1)

Division of medical Oncology A450B Starling Loving Hall, Ohio City

All Listed Sponsors

collaborator

Ohio State University

OTHER

lead

Palobiofarma SL

INDUSTRY